Thiazolidinediones and Glucagon‐Like Peptide‐1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Thiazolidinediones and Glucagon‐Like Peptide‐1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study
Authors
Keywords
-
Journal
HEPATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-06-16
DOI
10.1002/hep.32012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
- (2020) A. Mantovani et al. DIABETES & METABOLISM
- Liver‐related long‐term outcomes of thiazolidinedione use in persons with type 2 diabetes
- (2020) Fu‐Shun Yen et al. LIVER INTERNATIONAL
- Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
- (2020) Jianhong Zhu et al. Lancet Diabetes & Endocrinology
- Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B
- (2020) Terry Cheuk‐Fung Yip et al. JOURNAL OF VIRAL HEPATITIS
- Association of hepatocellular carcinoma with thiazolidinediones use
- (2020) Shih-Wei Lai et al. MEDICINE
- Pioglitazone Therapy in Patients With Stroke and Prediabetes
- (2019) J. David Spence et al. JAMA Neurology
- Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies
- (2019) Sebastien Haneuse et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts
- (2019) Myriam Alexander et al. BMC Medicine
- Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation
- (2019) Maurice B. Bizino et al. DIABETOLOGIA
- Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis
- (2019) Yue Zhou et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Gastrointestinal cancer incidence in type 2 diabetes mellitus; results from a large population-based cohort study in the UK
- (2018) Roy G.P.J. de Jong et al. Cancer Epidemiology
- Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes
- (2018) Fernando Bril et al. Clinical Gastroenterology and Hepatology
- Website and R Package for Computing E-Values
- (2018) Maya B. Mathur et al. EPIDEMIOLOGY
- Cancer recording in patients with and without type 2 diabetes in the Clinical Practice Research Datalink primary care data and linked hospital admission data: a cohort study
- (2018) Rachael Williams et al. BMJ Open
- A systematic review of observational studies of the association between pioglitazone use and bladder cancer
- (2018) E. Ripamonti et al. DIABETIC MEDICINE
- Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD
- (2018) Jinhua Yan et al. HEPATOLOGY
- Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis
- (2018) Kannan Sridharan et al. POSTGRADUATE MEDICAL JOURNAL
- The epidemiology of non-alcoholic fatty liver disease
- (2017) Stefano Bellentani LIVER INTERNATIONAL
- Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis
- (2017) Giovanni Musso et al. JAMA Internal Medicine
- Association between physical activity and risk of nonalcoholic fatty liver disease: a meta-analysis
- (2017) Shanhu Qiu et al. Therapeutic Advances in Gastroenterology
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
- (2016) A. Dutour et al. DIABETES OBESITY & METABOLISM
- Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies
- (2016) A. Katrina Loomis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- NAFLD and liver transplantation: Current burden and expected challenges
- (2016) Raluca Pais et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- (2016) Walter N. Kernan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pioglitazone use and risk of bladder cancer: population based cohort study
- (2016) Marco Tuccori et al. BMJ-British Medical Journal
- Pioglitazone use and risk of bladder cancer: population based cohort study
- (2016) Marco Tuccori et al. BMJ-British Medical Journal
- Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
- (2015) An Tang et al. DIABETES CARE
- Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis
- (2015) Siddharth Singh et al. HEPATOLOGY
- Data Resource Profile: Clinical Practice Research Datalink (CPRD)
- (2015) Emily Herrett et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes
- (2014) Yan Bi et al. ACTA DIABETOLOGICA
- Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
- (2014) Hui Fan et al. Arquivos Brasileiros de Endocrinologia e Metabologia
- Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes
- (2014) Raymond E. Soccio et al. Cell Metabolism
- Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
- (2014) Ning Shao et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
- (2012) M. J. Armstrong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cancer recording and mortality in the General Practice Research Database and linked cancer registries
- (2012) Rachael Boggon et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis
- (2010) M. O. Rakoski et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series
- (2010) Patrick R Kenny et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started